[go: up one dir, main page]

DE60202452C5 - PYRIDAZINONAL DOSE REDUCTASE INHIBITORS - Google Patents

PYRIDAZINONAL DOSE REDUCTASE INHIBITORS Download PDF

Info

Publication number
DE60202452C5
DE60202452C5 DE60202452T DE60202452T DE60202452C5 DE 60202452 C5 DE60202452 C5 DE 60202452C5 DE 60202452 T DE60202452 T DE 60202452T DE 60202452 T DE60202452 T DE 60202452T DE 60202452 C5 DE60202452 C5 DE 60202452C5
Authority
DE
Germany
Prior art keywords
pyridazin
alkyl
sulfonyl
het
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60202452T
Other languages
German (de)
Other versions
DE60202452D1 (en
DE60202452T2 (en
Inventor
Lakshman Banavara MYLARI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of DE60202452D1 publication Critical patent/DE60202452D1/en
Publication of DE60202452T2 publication Critical patent/DE60202452T2/en
Application granted granted Critical
Publication of DE60202452C5 publication Critical patent/DE60202452C5/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Verbindung der Formel I

Figure 00000001
deren Prodrug oder ein pharmazeutisch annehmbares Salz der Verbindung oder des Prodrug, worin
A für S, SO oder SO2 steht;
R1 und R2 unabhängig Wasserstoff oder Methyl bedeuten;
R3 für Het1, -CHR4Het1 oder NR6R7 steht;
R4 für Wasserstoff oder (C1-C3)Alkyl steht;
R6 für (C1-C6)Alkyl, Aryl oder Het2 steht;
R7 für Het3 steht;
Het1 für Pyridyl, Pyrimidyl, Pyrazinyl, Pyridazinyl, Chinolyl, Isochinolyl, Chinazolyl, Chinoxalyl, Phthalazinyl, Cinnolinyl, Naphthyridinyl, Pteridinyl, Pyrazinopyrazinyl, Pyrazinopyridazinyl, Pyrimidopyridazinyl, Pyrimidopyrimidyl, Pyridopyrimidyl, Pyridopyrazinyl, Pyridopyridazinyl, Pyrrolyl, Furanyl, Thienyl, Imidazolyl, Oxazolyl, Thiazolyl, Pyrazolyl, Isoxazolyl, Isothiazolyl, Triazolyl, Oxadiazolyl, Thiadiazolyl, Tetrazolyl, Indolyl, Benzofuranyl, Ben zothienyl, Benzimidazolyl, Benzoxazolyl, Benzothiazolyl, Indazolyl, Benzisoxazolyl, Benzisothiazolyl, Pyrrolopyridyl, Furopyridyl, Thienopyridyl, Imidazolopyridyl, Oxazolopyridyl, Thiazolopyridyl, Pyrazolopyridyl, Isoxazolopyridyl, Isothiazolopyridyl, Pyrrolopyrimidyl, Furopyrimidyl, Thienopyrimidyl; Imidazolopyrimidyl, Oxazolopyrimidyl, Thiazolopyrimidyl, Pyrazolopyrimidyl, Isoxazolopyrimidyl, Isothiazolopyrimidyl, Pyrrolopyrazinyl, Furopyrazinyl, Thienopyrazinyl, Imidazolopyrazinyl, Oxazolopyrazinyl, Thiazolopyrazinyl, Pyrazolopyrazinyl, Isoxazolopyrazinyl, Isothiazolopyrazinyl, Pyrrolopyridazinyl, Furopyridazinyl, Thienopyridazinyl, Imidazolopyridazinyl, Oxazolopyridazinyl, Thiazolopyridazinyl, Pyrazolopyridazinyl, Isoxazolopyridazinyl oder Isothiazolopyridazinyl steht, wobei Het1 durch bis zu vier...Compound of formula I
Figure 00000001
their prodrug or a pharmaceutically acceptable salt of the compound or prodrug, wherein
A is S, SO or SO 2 ;
R 1 and R 2 are independently hydrogen or methyl;
R 3 is Het 1 , -CHR 4 Het 1 or NR 6 R 7 ;
R 4 is hydrogen or (C 1 -C 3 ) alkyl;
R 6 is (C 1 -C 6 ) alkyl, aryl or Het 2 ;
R 7 is Het 3 ;
Het 1 represents pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, quinolyl, isoquinolyl, quinazolyl, quinoxalyl, phthalazinyl, cinnolinyl, naphthyridinyl, pteridinyl, pyrazinopyrazinyl, pyrazinopyridazinyl, pyrimidopyridazinyl, pyrimidopyrimidyl, pyridopyrimidyl, pyridopyrazinyl, pyridopyridazinyl, pyrrolyl, furanyl, thienyl, imidazolyl, oxazolyl , thiazolyl, pyrazolyl, isoxazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, indolyl, benzofuranyl, Ben zothienyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, pyrrolopyridyl, Furopyridyl, thienopyridyl, Imidazolopyridyl, oxazolopyridyl, thiazolopyridyl, pyrazolopyridyl, Isoxazolopyridyl, isothiazolopyridyl, pyrrolopyrimidyl, furopyrimidyl, thienopyrimidyl; Imidazolopyrimidyl, Oxazolopyrimidyl, Thiazolopyrimidyl, Pyrazolopyrimidyl, Isoxazolopyrimidyl, Isothiazolopyrimidyl, Pyrrolopyrazinyl, Furopyrazinyl, Thienopyrazinyl, Imidazolopyrazinyl, Oxazolopyrazinyl, Thiazolopyrazinyl, Pyrazolopyrazinyl, Isoxazolopyrazinyl, Isothiazolopyrazinyl, Pyrrolopyridazinyl, Furopyridazinyl, Thienopyridazinyl, Imidazolopyridazinyl, Oxazolopyridazinyl, Thiazolopyridazinyl, Pyrazolopyridazinyl, Isoxazolopyridazinyl or Isothiazolopyridazinyl, where Het 1 through up to four ...

Description

Auf den am 14.03.2006 eingegangenen Antrag der Patentinhaberin Pfizer Products Inc., Eastern Point Road, Groton, Connecticut, US wird das europäische Patent 137 32 59 mit Wirkung für die Bundesrepublik Deutschland (nationale Patentnummer DE 602 02 452 ) gemäß § 64 des Patentgesetzes entsprechend den Patentansprüchen 1 bis 17 beschränkt.The patent application of Pfizer Products Inc., Eastern Point Road, Groton, Connecticut, US, received on 14.03.2006, makes European patent 137 32 59 effective for the Federal Republic of Germany (national patent no DE 602 02 452 ) according to § 64 of the Patent Law according to claims 1 to 17 limited.

Claims (17)

Verbindung der Formel I
Figure 00020001
deren Prodrug oder ein pharmazeutisch annehmbares Salz der Verbindung oder des Prodrug, worin A für S, SO oder SO2 steht; R1 und R2 unabhängig Wasserstoff oder Methyl bedeuten; R3 für Het1, -CHR4Het1 oder NR6R7 steht; R4 für Wasserstoff oder (C1-C3)Alkyl steht; R6 für (C1-C6)Alkyl, Aryl oder Het2 steht; R7 für Het3 steht; Het1 für Pyridyl, Pyrimidyl, Pyrazinyl, Pyridazinyl, Chinolyl, Isochinolyl, Chinazolyl, Chinoxalyl, Phthalazinyl, Cinnolinyl, Naphthyridinyl, Pteridinyl, Pyrazinopyrazinyl, Pyrazinopyridazinyl, Pyrimidopyridazinyl, Pyrimidopyrimidyl, Pyridopyrimidyl, Pyridopyrazinyl, Pyridopyridazinyl, Pyrrolyl, Furanyl, Thienyl, Imidazolyl, Oxazolyl, Thiazolyl, Pyrazolyl, Isoxazolyl, Isothiazolyl, Triazolyl, Oxadiazolyl, Thiadiazolyl, Tetrazolyl, Indolyl, Benzofuranyl, Ben zothienyl, Benzimidazolyl, Benzoxazolyl, Benzothiazolyl, Indazolyl, Benzisoxazolyl, Benzisothiazolyl, Pyrrolopyridyl, Furopyridyl, Thienopyridyl, Imidazolopyridyl, Oxazolopyridyl, Thiazolopyridyl, Pyrazolopyridyl, Isoxazolopyridyl, Isothiazolopyridyl, Pyrrolopyrimidyl, Furopyrimidyl, Thienopyrimidyl; Imidazolopyrimidyl, Oxazolopyrimidyl, Thiazolopyrimidyl, Pyrazolopyrimidyl, Isoxazolopyrimidyl, Isothiazolopyrimidyl, Pyrrolopyrazinyl, Furopyrazinyl, Thienopyrazinyl, Imidazolopyrazinyl, Oxazolopyrazinyl, Thiazolopyrazinyl, Pyrazolopyrazinyl, Isoxazolopyrazinyl, Isothiazolopyrazinyl, Pyrrolopyridazinyl, Furopyridazinyl, Thienopyridazinyl, Imidazolopyridazinyl, Oxazolopyridazinyl, Thiazolopyridazinyl, Pyrazolopyridazinyl, Isoxazolopyridazinyl oder Isothiazolopyridazinyl steht, wobei Het1 durch bis zu vier Substituenten substituiert sein kann, die unabhängig ausgewählt sind aus Halogen, Formyl, (C1-C6)Alkoxycarbonyl, (C1-C6)Alkylenyloxycarbonyl, (C1-C4)Alkoxy-(C1-C4)Alkyl, C(OH)R12R13, (C1-C4)Alkylcarbonylamido, (C3-C7)-Cycloalkylcarbonylamido, Phenylcarbonylamido, Benzyl, Phenyl, Naphthyl, Imidazolyl, Pyridyl, Triazolyl, Benzimidazolyl, Oxazolyl, Isoxazolyl, Thiazolyl, Oxadiazolyl, Thiadiazolyl, Tetrazolyl, Thienyl, Benzothiazolyl, Pyrrolyl, Pyrazolyl, Chinolyl, Isochinolyl, Benzoxazolyl, Pyridazinyl, Pyridyloxy, Pyridylsulfonyl, Furanyl, Phenoxy, Thiophenoxy, (C1-C4)Alkylsulfenyl, (C1-C4)-Alkylsulfonyl, (C3-C7)Cycloalkyl, (C1-C6)Alkyl, das durch bis zu drei Fluoratome substituiert sein kann, (C1-C4)Alkoxy, das durch bis zu fünf Fluoratome substituiert sein kann; wobei die genannten Benzyl-, Phenyl-, Naphthyl-,Imidazolyl-, Pyridyl-, Triazolyl-, Benzimidazolyl-, Oxazolyl-, Isoxazolyl-, Thiazolyl-, Oxadiazolyl-, Thiadiazolyl-, Tetrazolyl-, Thienyl-, Benzothiazolyl-, Pyrrolyl-, Pyrazolyl-, Chinolyl-, Isochinolyl-, Benzoxazolyl-, Pyridazinyl-, Pyridyloxy-, Pyridylsulfonyl-, Furanyl-, Phenoxy- und Thiophenoxy-Gruppen in ihrer Eigenschaft als Substituenten von Het1 substituiert sein können durch bis zu drei Substituenten, die unabhängig ausgewählt sind aus Hydroxy, Halogen, Hydroxy-(C1-C4)Alkyl, (C1-C4)Alkoxy-(C1-C4)-Alkyl, (C1-C6)Alkylsulfenyl, (C1-C6)Alkylsulfinyl, (C1-C6)Alkylsulfonyl, (C1-C6)Alkyl, das durch bis zu fünf Fluoratome substituiert sein kann, und (C1- C4)Alkoxy, das durch bis zu fünf Fluoratome substituiert sein kann; wobei die genannten Imidazolyl-, Oxazolyl-, Isoxazolyl-, Thiazolyl- und Pyrazolyl-Gruppen in ihrer Eigenschaft als Substituenten von Het1 substituiert sein können durch ein oder zwei Substituenten, die unabhängig ausgewählt sind aus Hydroxy, Halogen, (C1-C4)Alkyl, Hydroxy-(C1-C4)Alkyl, (C1-C4)Alkoxy-(C1-C4)Alkyl, (C1-C4)Alkyl-phenyl, das im Phenylteil durch ein Chlor- oder Bromatom, durch Methoxy, Methyl oder SO2-Phenyl substituiert sein kann, wobei das SO2-Phenyl im Phenylteil substituiert sein kann durch ein Chlor- oder Bromatom, durch Methoxy, Methyl, (C1-C4)Alkyl, gegebenenfalls substituiert durch bis zu fünf Fluoratome, oder (C1-C4)Alkoxy, gegebenenfalls substituiert durch bis zu drei Fluoratome; R12 und R13 unabhängig Wasserstoff oder (C1-C4)Alkyl bedeuten; Het2 und Het3 unabhängig voneinander für Imidazolyl, Pyridyl, Triazolyl, Benzimidazolyl, Oxazolyl, Isoxazolyl, Thiazolyl, Oxadiazolyl, Thiadiazolyl, Tetrazolyl, Thienyl, Benzothiazolyl, Pyrrolyl, Pyrazolyl, Chinolyl, Isochinolyl, Benzoxazolyl, Pyridazinyl, Pyridyloxy, Pyridylsulfonyl, Furanyl, Phenoxy und Thiophenoxy stehen, wobei Het2 und Het3 gegebenenfalls jeweils unabhängig substituiert sind durch bis zu vier Substituenten, die unabhängig ausgewählt sind aus Halogen, Formyl, (C1-C6)Alkoxycarbonyl, (C1-C6)-Alkenyloxycarbonyl, (C1-C4)Alkoxy-(C1-C4)-alkyl, C(OH)R18R19, (C1-C4)Alkylcarbonylamido, (C3-C7)Cycloalkylcarbonylamido, Phenylcarbonylamido, Phenyl, Naphthyl, Imidazolyl, Pyridyl, Triazolyl, Benzimidazolyl, Oxazolyl, Isoxazolyl, Thiazolyl, Oxadiazolyl, Thiadiazolyl, Tetrazolyl, Thienyl, Benzothiazolyl, Pyrrolyl, Pyrazolyl, Chinolyl, Isochinolyl, Benzoxazolyl, Pyridazinyl, Pyridyloxy, Pyridylsulfonyl, Furanyl, Phenoxy, Thiophenoxy, (C1-C4)Alkylsulfenyl, (C1-C4)Alkylsulfonyl, (C3-C7)Cycloalkyl, (C1-C4)Alkyl, das durch bis zu drei Fluoratome substituiert sein kann, oder (C1-C4)Alkoxy, das durch bis zu fünf Fluoratome substituiert sein kann; wobei die genannten Phenyl-, Naphthyl-, Imidazolyl-, Pyridyl-, Triazolyl-, Benzimida zolyl-, Oxazolyl-, Isoxazolyl-, Thiazolyl-, Oxadiazolyl-, Thiadiazolyl-, Tetrazolyl-, Thienyl-, Benzothiazolyl-, Pyrrolyl-, Pyrazolyl-, Chinolyl-, Isochinolyl-, Benzoxazolyl-, Pyridazinyl-, Pyridyloxy-, Pyridylsulfonyl-, Furanyl-, Phenoxy- und Thiophenoxy-Gruppen in ihrer Eigenschaft als Substituenten von Het2 und Het3 durch bis zu drei Substituenten substituiert sein können, die unabhängig ausgewählt sind aus Hydroxy, Halogen, Hydroxy-(C1-C4)Alkyl, (C1-C4)Alkoxy-(C1-C4)alkyl, (C1-C4)Alkyl, das gegebenenfalls durch bis zu fünf Fluoratome substituiert ist, und (C1-C4)Alkoxy, das gegebenenfalls durch bis zu fünf Fluoratome substituiert ist; und wobei die genannten Imidazolyl-, Oxazolyl-, Isoxazolyl-, Thiazolyl- und Pyrazolyl-Grupppen in ihrer Eingenschaft als Substituenten von Het2 und Het3 substituiert sein können durch ein oder zwei Substituenten, die unabhängig ausgewählt sind aus Hydroxy, Halogen, Hydroxy-(C1-C4)Alkyl, (C1-C4)Alkoxy-(C1-C4)alkyl, (C1-C4)Alkyl, das gegebenenfalls durch bis zu fünf Fluoratome substituiert ist, und (C1-C4)Alkoxy, das gegebenenfalls durch bis zu drei Fluoratome substituiert ist; und R18 und R19 jeweils unabhängig für Wasserstoff oder (C1-C4)Alkyl stehen; wobei A für SO2 steht, wenn R3 die Gruppe NR6R7 bedeutet; mit Ausnahme von 6-(Pyridin-2-sulfinyl)-2H-pyridazin-3-on. Compound of formula I
Figure 00020001
their prodrug or a pharmaceutically acceptable salt of the compound or prodrug, wherein A is S, SO or SO 2 ; R 1 and R 2 are independently hydrogen or methyl; R 3 is Het 1 , -CHR 4 Het 1 or NR 6 R 7 ; R 4 is hydrogen or (C 1 -C 3 ) alkyl; R 6 is (C 1 -C 6 ) alkyl, aryl or Het 2 ; R 7 is Het 3 ; Het 1 represents pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, quinolyl, isoquinolyl, quinazolyl, quinoxalyl, phthalazinyl, cinnolinyl, naphthyridinyl, pteridinyl, pyrazinopyrazinyl, pyrazinopyridazinyl, pyrimidopyridazinyl, pyrimidopyrimidyl, pyridopyrimidyl, pyridopyrazinyl, pyridopyridazinyl, pyrrolyl, furanyl, thienyl, imidazolyl, oxazolyl , thiazolyl, pyrazolyl, isoxazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, indolyl, benzofuranyl, Ben zothienyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, pyrrolopyridyl, Furopyridyl, thienopyridyl, Imidazolopyridyl, oxazolopyridyl, thiazolopyridyl, pyrazolopyridyl, Isoxazolopyridyl, isothiazolopyridyl, pyrrolopyrimidyl, furopyrimidyl, thienopyrimidyl; Imidazolopyrimidyl, Oxazolopyrimidyl, Thiazolopyrimidyl, Pyrazolopyrimidyl, Isoxazolopyrimidyl, Isothiazolopyrimidyl, Pyrrolopyrazinyl, Furopyrazinyl, Thienopyrazinyl, Imidazolopyrazinyl, Oxazolopyrazinyl, Thiazolopyrazinyl, Pyrazolopyrazinyl, Isoxazolopyrazinyl, Isothiazolopyrazinyl, Pyrrolopyridazinyl, Furopyridazinyl, Thienopyridazinyl, Imidazolopyridazinyl, Oxazolopyridazinyl, Thiazolopyridazinyl, Pyrazolopyridazinyl, Isoxazolopyridazinyl or Isothiazolopyridazinyl, where Het 1 may be substituted by up to four substituents independently selected from halo, formyl, (C 1 -C 6 ) alkoxycarbonyl, (C 1 -C 6 ) alkylenyloxycarbonyl, (C 1 -C 4 ) alkoxy (C 1 -C 4 ) alkyl, C (OH) R 12 R 13 , (C 1 -C 4 ) alkylcarbonylamido, (C 3 -C 7 ) -cycloalkylcarbonylamido, phenylcarbonylamido, benzyl, phenyl, naphthyl, imidazolyl, pyridyl, triazolyl, benzimidazolyl, Oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, thienyl, benzothiazolyl, pyrrolyl, pyrazolyl, Ch inolyl, isoquinolyl, benzoxazolyl, pyridazinyl, pyridyloxy, pyridylsulfonyl, furanyl, phenoxy, thiophenoxy, (C 1 -C 4 ) alkylsulfenyl, (C 1 -C 4 ) alkylsulfonyl, (C 3 -C 7 ) cycloalkyl, (C 1 - C 6 ) alkyl which may be substituted by up to three fluorine atoms, (C 1 -C 4 ) alkoxy which may be substituted by up to five fluorine atoms; wherein said benzyl, phenyl, naphthyl, imidazolyl, pyridyl, triazolyl, benzimidazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, thienyl, benzothiazolyl, pyrrolyl, , Pyrazolyl, quinolyl, isoquinolyl, benzoxazolyl, pyridazinyl, pyridyloxy, pyridylsulfonyl, furanyl, phenoxy and thiophenoxy groups, in their capacity as substituents of Het 1, may be substituted by up to three substituents independently are selected from hydroxy, halogen, hydroxy (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy (C 1 -C 4 ) alkyl, (C 1 -C 6 ) alkylsulfenyl, (C 1 - C 6 ) alkylsulfinyl, (C 1 -C 6 ) alkylsulfonyl, (C 1 -C 6 ) alkyl which may be substituted by up to five fluorine atoms, and (C 1 -C 4 ) alkoxy substituted by up to five fluorine atoms can be; wherein said imidazolyl, oxazolyl, isoxazolyl, thiazolyl and pyrazolyl groups may be substituted in their capacity as substituents of Het 1 by one or two substituents independently selected from hydroxy, halogen, (C 1 -C 4 ) Alkyl, hydroxy- (C 1 -C 4 ) -alkyl, (C 1 -C 4 ) -alkoxy- (C 1 -C 4 ) -alkyl, (C 1 -C 4 ) -alkyl-phenyl, which in the phenyl moiety is replaced by a chlorine or bromine atom, may be substituted by methoxy, methyl or SO 2 -phenyl, wherein the SO 2 -phenyl in the phenyl moiety may be substituted by a chlorine or bromine atom, by methoxy, methyl, (C 1 -C 4 ) alkyl, optionally substituted by up to five fluorine atoms, or (C 1 -C 4 ) alkoxy, optionally substituted by up to three fluorine atoms; R 12 and R 13 are independently hydrogen or (C 1 -C 4 ) alkyl; Het 2 and Het 3 are each independently of one another imidazolyl, pyridyl, triazolyl, benzimidazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, thienyl, benzothiazolyl, pyrrolyl, pyrazolyl, quinolyl, isoquinolyl, benzoxazolyl, pyridazinyl, pyridyloxy, pyridylsulfonyl, furanyl, Phenoxy and thiophenoxy, where each of Het 2 and Het 3 is optionally independently substituted by up to four substituents independently selected from halo, formyl, (C 1 -C 6 ) alkoxycarbonyl, (C 1 -C 6 ) alkenyloxycarbonyl, (C 1 -C 4 ) alkoxy- (C 1 -C 4 ) -alkyl, C (OH) R 18 R 19 , (C 1 -C 4 ) -alkylcarbonylamido, (C 3 -C 7 ) -cycloalkylcarbonylamido, phenylcarbonylamido, phenyl, Naphthyl, imidazolyl, pyridyl, triazolyl, benzimidazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, thienyl, benzothiazolyl, pyrrolyl, pyrazolyl, quinolyl, isoquinolyl, benzoxazolyl, pyridazinyl, pyridyloxy, pyridylsulfonyl, furanyl, phenoxy, thiophenoxy, (C 1 -C 4 ) A alkylsulfenyl, (C 1 -C 4 ) alkylsulfonyl, (C 3 -C 7 ) cycloalkyl, (C 1 -C 4 ) alkyl, which may be substituted by up to three fluorine atoms, or (C 1 -C 4 ) alkoxy which may be substituted by up to five fluorine atoms; wherein said phenyl, naphthyl, imidazolyl, pyridyl, triazolyl, benzimidazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, thienyl, benzothiazolyl, pyrrolyl, pyrazolyl -, quinolyl, isoquinolyl, benzoxazolyl, pyridazinyl, pyridyloxy, pyridylsulfonyl, furanyl, phenoxy and thiophenoxy groups may be substituted in their capacity as substituents of Het 2 and Het 3 by up to three substituents, the are independently selected from hydroxy, halo, hydroxy (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkyl optionally substituted by bis is substituted to five fluorine atoms, and (C 1 -C 4 ) alkoxy optionally substituted by up to five fluorine atoms; and wherein said imidazolyl, oxazolyl, isoxazolyl, thiazolyl and pyrazolyl groups may be substituted in their nature as substituents of Het 2 and Het 3 by one or two substituents independently selected from hydroxy, halogen, hydroxy (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkyl, which is optionally substituted by up to five fluorine atoms, and (C 1 -C 4 ) alkoxy optionally substituted by up to three fluorine atoms; and R 18 and R 19 are each independently hydrogen or (C 1 -C 4 ) alkyl; where A is SO 2 , when R 3 is the group NR 6 R 7 ; with the exception of 6- (pyridine-2-sulfinyl) -2H-pyridazin-3-one. Verbindung nach Anspruch 1, deren Prodrug oder ein pharmazeutisch annehmbares Salz der Verbindung oder des Prodrug, worin A für SO steht, R1 und R2 jeweils Wasserstoff bedeuten, R3 für Het1 steht, das gegebenenfalls durch bis zu vier Substituenten substituiert ist.A compound according to claim 1, wherein the prodrug or a pharmaceutically acceptable salt of the compound or prodrug wherein A is SO, R 1 and R 2 are each hydrogen, R 3 is Het 1 optionally substituted by up to four substituents. Verbindung nach Anspruch 2, deren Prodrug oder ein pharmazeutisch annehmbares Salz der Verbindung oder des Prodrug, worin Het1 für 5H-Furo[3,2c]pyridin-4-on-2-yl, Furano[2,3b]pyridin-2-yl, Thieno[2,3b]pyridin-2-yl, Indol- 2-yl, Indol-3-yl, Benzofuran-2-yl, Benzothien-2-yl, Imidazo[1,2a]pyridin-3-yl, Pyrrol-1-yl, Imidazol-1-yl, Indazol-1-yl, Tetrahydrochinol-1-yl oder Tetrahydroindol-1-yl steht, wobei Het1 gegebenenfalls unabhängig substituiert ist durch bis zu zwei Substituenten, die jeweils unabhängig ausgewählt sind aus Fluor, Chlor, Brom, (C1-C6)Alkyl, (C1-C6)Alkoxy, Trifluormethyl, Hydroxy, Benzyl oder Phenyl, wobei Benzyl und Phenyl ihrerseits jeweils unabhängig voneinander substituiert sein können durch bis zu drei Substituenten, die ausgewählt sind aus Halogen, (C1-C6)Alkyl, (C1-C6)Alkoxy, (C1-C6)Alkylsulfonyl, (C1-C6)Alkylsulfinyl, (C1-C6)-Alkylsulfenyl, Trifluormethyl oder Hydroxy.A compound according to claim 2, its prodrug or a pharmaceutically acceptable salt of the compound or prodrug wherein Het 1 is 5H-furo [3,2c] pyridin-4-one-2-yl, furano [2,3b] pyridine-2-one yl, thieno [2,3b] pyridin-2-yl, indol-2-yl, indol-3-yl, benzofuran-2-yl, benzothien-2-yl, imidazo [1,2a] pyridin-3-yl, Pyrrol-1-yl, imidazol-1-yl, indazol-1-yl, tetrahydroquinol-1-yl or tetrahydroindol-1-yl, wherein Het 1 is optionally independently substituted by up to two substituents each independently selected from Fluorine, chlorine, bromine, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, trifluoromethyl, hydroxy, benzyl or phenyl, where benzyl and phenyl in turn each independently may be substituted by up to three substituents are selected from halogen, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) alkylsulfonyl, (C 1 -C 6 ) alkylsulfinyl, (C 1 -C 6 ) -alkylsulfenyl , Trifluoromethyl or hydroxy. Verbindung nach Anspruch 3, deren Prodrug oder ein pharmazeutisch annehmbares Salz der Verbindung oder des Prodrug, worin Het1 für Indol-2-yl, Benzofuran-2-yl, Benzothiophen-2-yl, Furano[2,3b]pyridin-2-yl, Thieno[2,3b]pyridin-2-yl oder Imidazo[1,2a]pyridin-4-yl steht, wobei Het1 gegebenenfalls unabhängig substituiert ist durch bis zu zwei Substituenten, die jeweils unabhängig ausgewählt sind aus Fluor, Chlor, Brom, (C1-C6)Alkyl, (C1-C6)Alkoxy, Trifluormethyl oder Phenyl, das unabhängig substituiert sein kann durch bis zu zwei Substituenten, die ausgewählt sind aus Fluor, Chlor und (C1-C6)Alkyl.A compound according to claim 3, its prodrug or a pharmaceutically acceptable salt of the compound or prodrug wherein Het 1 is indol-2-yl, benzofuran-2-yl, benzothiophene-2-yl, furano [2,3b] pyridine-2 yl, thieno [2,3b] pyridin-2-yl or imidazo [1,2a] pyridin-4-yl, where Het 1 is optionally independently substituted by up to two substituents each independently selected from fluoro, chloro, Bromine, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, trifluoromethyl or phenyl, which may be independently substituted by up to two substituents selected from fluoro, chloro and (C 1 -C 6 ) alkyl. Verbindung nach Anspruch 4, deren Prodrug oder ein pharmazeutisch annehmbares Salz der Verbindung oder des Prodrug, worin Het1 für Benzofuran-2-yl steht, das gegebenenfalls substituiert ist durch bis zu zwei Substituenten, die jeweils unabhängig ausgewählt sind aus Methyl, Methoxy, Chlor, Fluor, Ethyl, 4-Fluorphenyl, Trifluormethyl, Isopropyl, Phenyl und Hydroxy.A compound according to claim 4, its prodrug or a pharmaceutically acceptable salt of the compound or prodrug wherein Het 1 is benzofuran-2-yl optionally substituted by up to two substituents each independently selected from methyl, methoxy, chloro , Fluoro, ethyl, 4-fluorophenyl, trifluoromethyl, isopropyl, phenyl and hydroxy. Verbindung nach Anspruch 5, deren Prodrug oder ein pharmazeutisch annehmbares Salz der Verbindung oder des Prodrug, worin Het1 für 5-Chlor-benzofuran-2-yl, 5,7-Dichlor-benzofuran-2-yl, Benzofuran-2-yl, 5-Chlor-3-methyl-benzofuran-2-yl, 5-Fluor-3-methyl-benzofuran-2-yl, 3-Methyl-5-trifluormethyl-benzofuran-2-yl, 5-Chlor-3-phenyl-benzofuran-2-yl, 3-Phenyl-benzofuran-2-yl, 3- (4-Fluor-phenyl)-benzofuran-2-yl, 5-Chlor-benzofuran-2-yl, 3-Ethyl-5-methyl-benzofuran-2-yl oder 3-Methyl-benzofuran-2-yl steht.A compound according to claim 5, its prodrug or a pharmaceutically acceptable salt of the compound or prodrug wherein Het 1 is 5-chloro-benzofuran-2-yl, 5,7-dichloro-benzofuran-2-yl, benzofuran-2-yl, 5-chloro-3-methyl-benzofuran-2-yl, 5-fluoro-3-methyl-benzofuran-2-yl, 3-methyl-5-trifluoromethyl-benzofuran-2-yl, 5-chloro-3-phenyl benzofuran-2-yl, 3-phenyl-benzofuran-2-yl, 3- (4-fluoro-phenyl) -benzofuran-2-yl, 5-chloro-benzofuran-2-yl, 3-ethyl-5-methyl benzofuran-2-yl or 3-methylbenzofuran-2-yl. Verbindung nach Anspruch 5, deren Prodrug oder ein pharmazeutisch annehmbares Salz der Verbindung oder des Prodrug, worin Het1 für 3-Methylbenzofuran-2-yl steht, das gegebenenfalls durch einen zusätzlichen Substituenten substituiert ist, der unabhängig ausgewählt ist aus Methyl, Methoxy, Chlor, Fluor, Ethyl, 4-Fluorphenyl, Trifluormethyl, Isopropyl, Phenyl und Hydroxy.A compound according to claim 5, its prodrug or a pharmaceutically acceptable salt of the compound or prodrug wherein Het 1 is 3-methylbenzofuran-2-yl optionally substituted by an additional substituent independently selected from methyl, methoxy, chloro , Fluoro, ethyl, 4-fluorophenyl, trifluoromethyl, isopropyl, phenyl and hydroxy. Verbindung nach Anspruch 7, deren Prodrug oder ein pharmazeutisch annehmbares Salz der Verbindung oder des Prodrug, worin der zusätzliche Substituent 5-Chlor darstellt.A compound according to claim 7, its prodrug or a pharmaceutically acceptable salt of the compound or prodrug, wherein the additional substituent Represents 5-chloro. Verbindung nach Anspruch 5, deren Prodrug oder ein pharmazeutisch annehmbares Salz der Verbindung oder des Prodrug, ausgewählt aus 6-(5-Chlor-3-methyl-benzofuran-2-sulfonyl)-2H-pyridazin-3-on, 6-(5-Fluor-3-methyl-benzofuran-2-sulfonyl)-2H-pyridazin-3-on und 6-(5-Trifluormethyl-3-methyl-benzofuran-2-sulfonyl)-2H-pyridazin-3-on.A compound according to claim 5, its prodrug or a pharmaceutically acceptable salt of the compound or prodrug, selected from 6- (5-chloro-3-methylbenzofuran-2-sulfonyl) -2H-pyridazin-3-one, 6- (5-fluoro-3-methyl-benzofuran-2-sulfonyl) -2H-pyridazin-3-one and 6- (5-trifluoromethyl-3-methyl-benzofuran-2-sulfonyl) -2H-pyridazin-3-one. Verbindung, ausgewählt aus 6-(Indol-2-sulfonyl)-2H-pyridazin-3-on; 6-(5-Chlor-3-methyl-benzofuran-2-sulfonyl)-2H-pyridazin-3-on; 6-(Benzofuran-2-sulfonyl)-2H-pyridazin-3-on; 6-(5-Methoxy-benzofuran-2-sulfonyl)-2H-pyridazin-3-on; 6-(3,5-Dimethyl-benzofuran-2-sulfonyl)-2H-pyridazin-3-on; 6-(5,7-Dichlor-benzofuran-2-sulfonyl)-2H-pyridazin-3-on; 6-(5-Chlor-benzofuran-2-sulfonyl)-2H-pyridazin-3-on; 6-(3-Methyl-benzofuran-2-sulfonyl)-2H-pyridazin-3-on; 6-(5-Trifluormethyl-3-methyl-benzofuran-2-sulfonyl)-2H-pyridazin-3-on; 6-(5-Chlor-3-isopropyl-benzofuran-2-sulfonyl)-2H-pyridazin-3-on; 6-(5-Fluor-3-methyl-benzofuran-2-sulfonyl)-2H-pyridazin-3-on; 6-(6-Chlor-3-methyl-benzofuran-2-sulfonyl)-2H-pyridazin-3-on; 6-(3-Hydroxy-benzofuran-2-sulfonyl)-2H-pyridazin-3-on; 6-(5-Chlor-3-hydroxy-benzofuran-2-sulfonyl)-2H-pyridazin-3-on; 6-(5-Chlor-3-methyl-benzothiophen-2-sulfonyl)-2H-pyridazin-3-on; 6-(5-Methyl-benzothi ophen-2-sulfonyl)-2H-pyridazin-3-on; 6-benzothiophen-2-sulfonyl)-2H-pyridazin-3-on; 6-(3-Phenyl-benzofuran-2-sulfonyl)-2H-pyridazin-3-on; 6-(3-[4-Fluorphenyl]-benzofuran-2-methylsulfonyl)-2H-pyridazin-3-on; 6-(Thieno[2,3b]pyridin-2-sulfonyl)-2H-pyridazin-3-on; 2-(6-Oxo-1,6-dihydro-pyridazin-3-sulfonyl)-5H-furo[3,2-c]pyridin-4-on; 6-(5-Chlor-3-ethyl-benzofuran-2-sulfonyl)-2H-pyridazin-3-on; 6-(Imidazo[1,2a]pyridin-3-sulfonyl)-2H-pyridazin-3-on; 6-(6-Chlor-indol-2-sulfonyl)-2H-pyridazin-3-on; 6-(5-Methoxy-indol-2-sulfonyl)-2H-pyridazin-3-on; 6-(5-Chlor-indol-2-sulfonyl)-2H-pyridazin-3-on; 6-(6-Fluor-indol-2-sulfonyl)-2H-pyridazin-3-on; 6-(5,6-Methylendioxy-indol-2-sulfonyl)-2H-pyridazin-3-on; 6-(7-Chlor-indol-2-sulfonyl)-2H-pyridazin-3-on; 6-(5-Chlor-3-phenyl-2-sulfonyl)-2H-pyridazin-3-on; 6-(3-Chlor-indol-2-sulfonyl)-2H-pyridazin-3-on; 6-(N-Benzylindol-5-sulfonyl)-2H-pyridazin-3-on; 6-(5-Chlor-3-methyl-benzofuran-2-methylsulfonyl)-2H-pyridazin-3-on; 6-(Indol-3-sulfonyl)-2H-pyridazin-3-on; 6-(N-Methylindol-2-sulfonyl)-2H-pyridazin-3-on; 6-(Pyrrol-1-sulfonyl)-2H-pyridazin-3-on; 6-(Imidazol-1-sulfonyl)2H-pyridazin-3-on; 6-(Indol-1-sulfonyl)-2H-pyridazin-3-on; 6-(3-Chlor-indol-1-sulfonyl)-2H-pyridazin-3-on; 6-(3-Chlor-indazol-1-sulfonyl)-2H-pyridazin-3-on; 6-(3-Methyl-indol-1-sulfonyl)-2H-pyridazin-3-on; 6-(Tetrahydrochinolin-1-sulfonyl)-2H-pyridazin-3-on; 6-(3-[4-Fluorphenyl]-benzofuran-2-sulfonyl)-2H-pyridazin-3-on; 6-(Imidazo[1,2a]pyridin-4-sulfonyl)-2H-pyridazin-3-on und 6-(2,3-Tetrahydroindol-1-sulfonyl)-2H-pyridazin-3-on.Compound selected from 6- (indole-2-sulfonyl) -2H-pyridazin-3-one; 6- (5-chloro-3-methyl-benzofuran-2-sulfonyl) -2H-pyridazin-3-one; 6- (Benzofu ran-2-sulfonyl) -2H-pyridazin-3-one; 6- (5-methoxy-benzofuran-2-sulfonyl) -2H-pyridazin-3-one; 6- (3,5-dimethyl-benzofuran-2-sulfonyl) -2H-pyridazin-3-one; 6- (5,7-dichloro-benzofuran-2-sulfonyl) -2H-pyridazin-3-one; 6- (5-chloro-benzofuran-2-sulfonyl) -2H-pyridazin-3-one; 6- (3-methyl-benzofuran-2-sulfonyl) -2H-pyridazin-3-one; 6- (5-trifluoromethyl-3-methyl-benzofuran-2-sulfonyl) -2H-pyridazin-3-one; 6- (5-chloro-3-isopropyl-benzofuran-2-sulfonyl) -2H-pyridazin-3-one; 6- (5-fluoro-3-methyl-benzofuran-2-sulfonyl) -2H-pyridazin-3-one; 6- (6-chloro-3-methyl-benzofuran-2-sulfonyl) -2H-pyridazin-3-one; 6- (3-hydroxy-benzofuran-2-sulfonyl) -2H-pyridazin-3-one; 6- (5-chloro-3-hydroxy-benzofuran-2-sulfonyl) -2H-pyridazin-3-one; 6- (5-chloro-3-methyl-benzothiophene-2-sulfonyl) -2H-pyridazin-3-one; 6- (5-methylbenzothiophene-2-sulfonyl) -2H-pyridazin-3-one; 6-benzothiophene-2-sulfonyl) -2H-pyridazin-3-one; 6- (3-phenyl-benzofuran-2-sulfonyl) -2H-pyridazin-3-one; 6- (3- [4-fluorophenyl] -benzofuran-2-methylsulfonyl) -2H-pyridazin-3-one; 6- (thieno [2,3-b] pyridine-2-sulfonyl) -2H-pyridazin-3-one; 2- (6-oxo-1,6-dihydro-pyridazin-3-sulfonyl) -5H-furo [3,2-c] pyridin-4-one; 6- (5-chloro-3-ethyl-benzofuran-2-sulfonyl) -2H-pyridazin-3-one; 6- (imidazo [1,2a] pyridine-3-sulfonyl) -2H-pyridazin-3-one; 6- (6-chloro-indole-2-sulfonyl) -2H-pyridazin-3-one; 6- (5-methoxy-indole-2-sulfonyl) -2H-pyridazin-3-one; 6- (5-chloro-indole-2-sulfonyl) -2H-pyridazin-3-one; 6- (6-fluoro-indole-2-sulfonyl) -2H-pyridazin-3-one; 6- (5,6-methylenedioxy-indole-2-sulfonyl) -2H-pyridazin-3-one; 6- (7-chloro-indole-2-sulfonyl) -2H-pyridazin-3-one; 6- (5-chloro-3-phenyl-2-sulfonyl) -2H-pyridazin-3-one; 6- (3-chloro-indole-2-sulfonyl) -2H-pyridazin-3-one; 6- (N-benzylindole-5-sulfonyl) -2H-pyridazin-3-one; 6- (5-chloro-3-methyl-benzofuran-2-methylsulfonyl) -2H-pyridazin-3-one; 6- (indole-3-sulfonyl) -2H-pyridazin-3-one; 6- (N-methylindole-2-sulfonyl) -2H-pyridazin-3-one; 6- (pyrrole-1-sulfonyl) -2H-pyridazin-3-one; 6- (imidazole-1-sulfonyl) 2H-pyridazin-3-one; 6- (indole-1-sulfonyl) -2H-pyridazin-3-one; 6- (3-chloro-indole-1-sulfonyl) -2H-pyridazin-3-one; 6- (3-chloro-indazole-1-sulfonyl) -2H-pyridazin-3-one; 6- (3-methyl-indole-1-sulfonyl) -2H-pyridazin-3-one; 6- (tetrahydroquinoline-1-sulfonyl) -2H-pyridazin-3-one; 6- (3- [4-fluorophenyl] -benzofuran-2-sulfonyl) -2H-pyridazin-3-one; 6- (imidazo [1,2a] pyridine-4-sulfonyl) -2H-pyridazin-3-one and 6- (2,3-tetrahydroindole-1-sulfonyl) -2H-pyridazin-3-one. Pharmazeutische Komposition, enthaltend eine Verbindung der Formel I
Figure 00080001
deren Prodrug oder ein pharmazeutisch annehmbares Salz der Verbindung oder des Prodrug, worin A für S, SO oder SO steht; R1 und R2 unabhängig Wasserstoff oder Methyl bedeuten; R3 für Het1, -CHR4Het1 oder NR6R7 steht; R4 für Wasserstoff oder (C1-C3)Alkyl steht; R6 für (C1-C6)Alkyl, Aryl oder Het2 steht; R7 für Het3 steht; Het1 für Pyridyl, Pyrimidyl, Pyrazinyl, Pyridazinyl, Chinolyl, Isochinolyl, Chinazolyl, Chinoxalyl, Phthalazinyl, Cinnolinyl, Naphthyridinyl, Pteridinyl, Pyrazinopyrazinyl, Pyrazinopyridazinyl, Pyrimidopyridazinyl, Pyrimidopyrimidyl, Pyridopyrimidyl, Pyridopyrazinyl, Pyridopyridazinyl, Pyrrolyl, Furanyl, Thienyl, Imidazolyl, Oxazolyl, Thiazolyl, Pyrazolyl, Isoxazolyl, Isothiazolyl, Triazolyl, Oxadiazolyl, Thiadiazolyl, Tetrazolyl, Indolyl, Benzofuranyl, Benzothienyl, Benzimidazolyl, Benzoxazolyl, Benzothiazolyl, Indazolyl, Benzisoxazolyl, Benzisothiazolyl, Pyrrolopyridyl, Furopyridyl, Thienopyridyl, Imidazolopyridyl, Oxazolopyridyl, Thiazolopyridyl, Pyrazolopyridyl, Isoxazolopyridyl, Isothiazolopyridyl, Pyrrolopyrimidyl, Furopyrimidyl, Thienopyrimidyl, Imidazolopyrimidyl, Oxazolopyrimidyl, Thiazolopyrimidyl, Pyrazolopyrimidyl, Isoxazolopyrimidyl, Isothiazolopyrimidyl, Pyrrolopyrazinyl, Furopyrazinyl, Thienopyrazinyl, Imidazolopyrazinyl, Oxazolopyrazinyl, Thiazolopyrazinyl, Pyrazolopyrazinyl, Isoxazolopyrazinyl, Isothiazolopyrazinyl, Pyrrolopyridazinyl, Furopyridazinyl, Thienopyridazinyl, Imidazolopyridazinyl, Oxazolopyridazinyl, Thiazolopyridazinyl, Pyrazolopyridazinyl, Isoxazolopyridazinyl oder Isothiazolopyridazinyl steht, wobei Het1 durch bis zu vier Substituenten substituiert sein kann, die unabhängig ausgewählt sind aus Halogen, Formyl, (C1-C6)Alkoxycarbonyl, (C1-C6)Alkylenyloxycarbonyl, (C1- C4)Alkoxy-(C1-C4)Alkyl, C(OH)R12R13, (C1-C4)Alkylcarbonylamido, (C3-C7)-Cycloalkylcarbonylamido, Phenylcarbonylamido, Benzyl, Phenyl, Naphthyl, Imidazolyl, Pyridyl, Triazolyl, Benzimidazolyl, Oxazolyl, Isoxazolyl, Thiazolyl, Oxadiazolyl, Thiadiazolyl, Tetrazolyl, Thienyl, Benzothiazolyl, Pyrrolyl, Pyrazolyl, Chinolyl, Isochinolyl, Benzoxazolyl, Pyridazinyl, Pyridyloxy, Pyridylsulfonyl, Furanyl, Phenoxy, Thiophenoxy, (C1-C4)Alkylsulfenyl, (C1-C4)-Alkylsulfonyl, (C3-C7)Cycloalkyl, (C1-C6)Alkyl, das durch bis zu drei Fluoratome substituiert sein kann, (C1-C4)Alkoxy, das durch bis zu fünf Fluoratome substituiert sein kann; wobei die genannten Benzyl-, Phenyl-, Naphthyl-, Imidazolyl-, Pyridyl-, Triazolyl-, Benzimidazolyl-, Oxazolyl-, Isoxazolyl-, Thiazolyl-, Oxadiazolyl-, Thiadiazolyl-, Tetrazolyl-, Thienyl-, Benzothiazolyl-, Pyrrolyl-, Pyrazolyl-, Chinolyl-, Isochinolyl-, Benzoxazolyl-, Pyridazinyl-, Pyridyloxy-, Pyridylsulfonyl-, Furanyl-, Phenoxy- und Thiophenoxy-Gruppen in ihrer Eigenschaft als Substituenten von Het1 substituiert sein können durch bis zu drei Substituenten, die unabhängig ausgewählt sind aus Hydroxy, Halogen, Hydroxy-(C1-C4)Alkyl, (C1-C4)Alkoxy-(C1-C4)-Alkyl, (C1-C6)Alkylsulfenyl, (C1-C6)Alkylsulfinyl, (C1-C6)Alkylsulfonyl, (C1-C6)Alkyl, das durch bis zu fünf Fluoratome substituiert sein kann, und (C1-C4)Alkoxy, das durch bis zu fünf Fluoratome substituiert sein kann; wobei die genannten Imidazolyl-, Oxazolyl-, Isoxazolyl-, Thiazolyl- und Pyrazolyl-Gruppen in ihrer Eigenschaft als Substituenten von Het1 substituiert sein können durch ein oder zwei Substituenten, die unabhängig ausgewählt sind aus Hydroxy, Halogen, (C1-C4)Alkyl, Hydroxy-(C1-C4)Alkyl, (C1-C4)Alkoxy-(C1-C4)Alkyl, (C1-C4)Alkyl-phenyl, das im Phenylteil durch ein Chlor- oder Bromatom, durch Methoxy, Methyl oder SO2-Phenyl substituiert sein kann, wobei das SO2-Phenyl im Phenylteil substituiert sein kann durch ein Chlor- oder Bromatom, durch Methoxy, Methyl, (C1-C4)Alkyl, gegebenenfalls substituiert durch bis zu fünf Fluoratome, oder (C1-C4)Alkoxy, gegebenenfalls substituiert durch bis zu drei Fluoratome; R12 und R13 unabhängig Wasserstoff oder (C1-C4)Alkyl bedeuten; Het2 und Het3 unabhängig voneinander für Imidazolyl, Pyridyl, Triazolyl, Benzimidazolyl, Oxazolyl, Isoxazolyl, Thiazolyl, Oxadiazolyl, Thiadiazolyl, Tetrazolyl, Thienyl, Benzothiazolyl, Pyrrolyl, Pyrazolyl, Chinolyl, Isochinolyl, Benzoxazolyl, Pyridazinyl, Pyridyloxy, Pyridylsulfonyl, Furanyl, Phenoxy und Thiophenoxy stehen, wobei Het2 und Het3 gegebenenfalls jeweils unabhängig substituiert sind durch bis zu vier Substituenten, die unabhängig ausgewählt sind aus Halogen, Formyl, (C1-C6)Alkoxycarbonyl, (C1-C6)-Alkenyloxycarbonyl, (C1-C4)Alkoxy-(C1-C4)-alkyl, C(OH)R18R19, (C1-C4)Al kylcarbonylamido, (C3-C7)Cycloalkylcarbonylamido, Phenylcarbonylamido, Phenyl, Naphthyl, Imidazolyl, Pyridyl, Triazolyl, Benzimidazolyl, Oxazolyl, Isoxazolyl, Thiazolyl, Oxadiazolyl, Thiadiazolyl, Tetrazolyl, Thienyl, Benzothiazolyl, Pyrrolyl, Pyrazolyl, Chinolyl, Isochinolyl, Benzoxazolyl, Pyridazinyl, Pyridyloxy, Pyridylsulfonyl, Furanyl, Phenoxy, Thiophenoxy, (C1-C4)Alkylsulfenyl, (C1-C4)Alkylsulfonyl, (C3-C7)Cycloalkyl, (C1-C4)Alkyl, das durch bis zu drei Fluoratome substituiert sein kann, oder (C1-C4)Alkoxy, das durch bis zu fünf Fluoratome substituiert sein kann; wobei die genannten Phenyl-, Naphthyl-,Imidazolyl-, Pyridyl-, Triazolyl-, Benzimidazolyl-, Oxazolyl-, Isoxazolyl-, Thiazolyl-, Oxadiazolyl-, Thiadiazolyl-, Tetrazolyl-, Thienyl-, Benzothiazolyl-, Pyrrolyl-, Pyrazolyl-, Chinolyl-, Isochinolyl-, Benzoxazolyl-, Pyridazinyl-, Pyridyloxy-, Pyridylsulfonyl-, Furanyl-, Phenoxy- und Thiophenoxy-Gruppen in ihrer Eigenschaft als Substituenten von Het2 und Het3 durch bis zu drei Substituenten substituiert sein können, die unabhängig ausgewählt sind aus Hydroxy, Halogen, Hydroxy-(C1-C4)Alkyl, (C1-C4)Alkoxy-(C1-C4)alkyl, (C1-C4)Alkyl, das gegebenenfalls durch bis zu fünf Fluoratome substituiert ist, und (C1-C4)Alkoxy, das gegebenenfalls durch bis zu fünf Fluoratome substituiert ist; und wobei die genannten Imidazolyl-, Oxazolyl-, Isoxazolyl-, Thiazolyl- und Pyrazolyl-Grupppen in ihrer Eingenschaft als Substituenten von Het2 und Het3 substituiert sein können durch ein oder zwei Substituenten, die unabhängig ausgewählt sind aus Hydroxy, Halogen, Hydroxy-(C1-C4)Alkyl, (C1-C4)Alkoxy-(C1-C4)al kyl, (C1-C4)Alkyl, das gegebenenfalls durch bis zu fünf Fluoratome substituiert ist, und (C1-C4)Alkoxy, das gegebenenfalls durch bis zu drei Fluoratome substituiert ist; und R18 und R1 9 jeweils unabhängig für Wasserstoff oder (C1-C4)Alkyl stehen; wobei A für SO2 steht, wenn R3 die Gruppe NR6R7 bedeutet; sowie einen pharmazeutisch annehmbaren Hilfs- oder Trägerstoff oder Verdünner.Pharmaceutical composition containing a compound of the formula I.
Figure 00080001
their prodrug or a pharmaceutically acceptable salt of the compound or prodrug, wherein A is S, SO or SO; R 1 and R 2 are independently hydrogen or methyl; R 3 is Het 1 , -CHR 4 Het 1 or NR 6 R 7 ; R 4 is hydrogen or (C 1 -C 3 ) alkyl; R 6 is (C 1 -C 6 ) alkyl, aryl or Het 2 ; R 7 is Het 3 ; Het 1 represents pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, quinolyl, isoquinolyl, quinazolyl, quinoxalyl, phthalazinyl, cinnolinyl, naphthyridinyl, pteridinyl, pyrazinopyrazinyl, pyrazinopyridazinyl, pyrimidopyridazinyl, pyrimidopyrimidyl, pyridopyrimidyl, pyridopyrazinyl, pyridopyridazinyl, pyrrolyl, furanyl, thienyl, imidazolyl, oxazolyl , thiazolyl, pyrazolyl, isoxazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, pyrrolopyridyl, Furopyridyl, thienopyridyl, Imidazolopyridyl, oxazolopyridyl, thiazolopyridyl, pyrazolopyridyl, Isoxazolopyridyl , Isothiazolopyridyl, pyrrolopyrimidyl, furopyrimidyl, thienopyrimidyl, imidazolopyrimidyl, oxazolopyrimidyl, thiazolopyrimidyl, pyrazolopyrimidyl, isoxazolopyrimidyl, isothiazolopyrimidyl, pyrrolopyrazinyl, furopyrazinyl, thienopyrazinyl, imidazolopyrazinyl, oxazolopyrazinyl, thiazolopyrazinyl, pyrazolopy razinyl, isoxazolopyrazinyl, isothiazolopyrazinyl, pyrrolopyridazinyl, furopyridazinyl, thienopyridazinyl, imidazolopyridazinyl, oxazolopyridazinyl, thiazolopyridazinyl, pyrazolopyridazinyl, isoxazolopyridazinyl or isothiazolopyridazinyl, wherein Het 1 may be substituted by up to four substituents independently selected from halogen, formyl, (C 1 - C 6 ) alkoxycarbonyl, (C 1 -C 6 ) alkylenyloxycarbonyl, (C 1 -C 4 ) alkoxy (C 1 -C 4 ) alkyl, C (OH) R 12 R 13 , (C 1 -C 4 ) alkylcarbonylamido, (C 3 -C 7 ) -cycloalkylcarbonylamido, phenylcarbonylamido, benzyl, phenyl, naphthyl, imidazolyl, pyridyl, triazolyl, benzimidazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, thienyl, benzothiazolyl, pyrrolyl, pyrazolyl, quinolyl, isoquinolyl, Benzoxazolyl, pyridazinyl, pyridyloxy, pyridylsulfonyl, furanyl, phenoxy, thiophenoxy, (C 1 -C 4 ) alkylsulfenyl, (C 1 -C 4 ) alkylsulfonyl, (C 3 -C 7 ) cycloalkyl, (C 1 -C 6 ) alkyl by up to three fluorine atoms may be substituted (C 1 -C 4 ) alkoxy which may be substituted by up to five fluorine atoms; wherein said benzyl, phenyl, naphthyl, imidazolyl, pyridyl, triazolyl, benzimidazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, thienyl, benzothiazolyl, pyrrolyl, , Pyrazolyl, quinolyl, isoquinolyl, benzoxazolyl, pyridazinyl, pyridyloxy, pyridylsulfonyl, furanyl, phenoxy and thiophenoxy groups, in their capacity as substituents of Het 1, may be substituted by up to three substituents independently are selected from hydroxy, halogen, hydroxy (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy (C 1 -C 4 ) alkyl, (C 1 -C 6 ) alkylsulfenyl, (C 1 - C 6 ) alkylsulfinyl, (C 1 -C 6 ) alkylsulfonyl, (C 1 -C 6 ) alkyl, which may be substituted by up to five fluorine atoms, and (C 1 -C 4 ) alkoxy, the may be substituted by up to five fluorine atoms; wherein said imidazolyl, oxazolyl, isoxazolyl, thiazolyl and pyrazolyl groups may be substituted in their capacity as substituents of Het 1 by one or two substituents independently selected from hydroxy, halogen, (C 1 -C 4 ) Alkyl, hydroxy- (C 1 -C 4 ) -alkyl, (C 1 -C 4 ) -alkoxy- (C 1 -C 4 ) -alkyl, (C 1 -C 4 ) -alkyl-phenyl, which in the phenyl moiety is replaced by a chlorine or bromine atom, may be substituted by methoxy, methyl or SO 2 -phenyl, wherein the SO 2 -phenyl in the phenyl moiety may be substituted by a chlorine or bromine atom, by methoxy, methyl, (C 1 -C 4 ) alkyl, optionally substituted by up to five fluorine atoms, or (C 1 -C 4 ) alkoxy, optionally substituted by up to three fluorine atoms; R 12 and R 13 are independently hydrogen or (C 1 -C 4 ) alkyl; Het 2 and Het 3 are each independently of one another imidazolyl, pyridyl, triazolyl, benzimidazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, thienyl, benzothiazolyl, pyrrolyl, pyrazolyl, quinolyl, isoquinolyl, benzoxazolyl, pyridazinyl, pyridyloxy, pyridylsulfonyl, furanyl, Phenoxy and thiophenoxy, where each of Het 2 and Het 3 is optionally independently substituted by up to four substituents independently selected from halo, formyl, (C 1 -C 6 ) alkoxycarbonyl, (C 1 -C 6 ) alkenyloxycarbonyl, (C 1 -C 4 ) alkoxy (C 1 -C 4 ) alkyl, C (OH) R 18 R 19 , (C 1 -C 4 ) alkylcarbonylamido, (C 3 -C 7 ) cycloalkylcarbonylamido, phenylcarbonylamido, phenyl , Naphthyl, imidazolyl, pyridyl, triazolyl, benzimidazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, thienyl, benzothiazolyl, pyrrolyl, pyrazolyl, quinolyl, isoquinolyl, benzoxazolyl, pyridazinyl, pyridyloxy, pyridylsulfonyl, furanyl, phenoxy, thiophenoxy, C 1 -C 4 ) Alkylsulfenyl, (C 1 -C 4 ) alkylsulfonyl, (C 3 -C 7 ) cycloalkyl, (C 1 -C 4 ) alkyl, which may be substituted by up to three fluorine atoms, or (C 1 -C 4 ) alkoxy, the may be substituted by up to five fluorine atoms; wherein said phenyl, naphthyl, imidazolyl, pyridyl, triazolyl, benzimidazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, thienyl, benzothiazolyl, pyrrolyl, pyrazolyl, , Quinolyl, isoquinolyl, benzoxazolyl, pyridazinyl, pyridyloxy, pyridylsulfonyl, furanyl, phenoxy and thiophenoxy groups may be substituted in their capacity as substituents of Het 2 and Het 3 by up to three substituents independently are selected from hydroxy, halogen, hydroxy (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkyl, which may be substituted by up to five fluorine atoms are substituted, and (C 1 -C 4 ) alkoxy optionally substituted by up to five fluorine atoms; and wherein said imidazolyl, oxazolyl, isoxazolyl, thiazolyl and pyrazolyl groups may be substituted in their nature as substituents of Het 2 and Het 3 by one or two substituents independently selected from hydroxy, halogen, hydroxy (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkyl optionally substituted by up to five fluorine atoms, and (C 1 -C 4 ) alkoxy which is optionally substituted by up to three fluorine atoms; and R 18 and R 1 9 are each independently hydrogen or (C 1 -C 4) alkyl; where A is SO 2 , when R 3 is the group NR 6 R 7 ; and a pharmaceutically acceptable excipient or carrier or diluent. Verwendung einer Verbindung der Formel I nach Anspruch 11, von deren Prodrug oder eines pharmazeutisch annehmbaren Salzes der Verbindung oder des Prodrug zur Herstellung eines Arzneimittels zur Behandlung von Herzgewebe-Ischämie bei Säugetieren oder Menschen.Use of a compound of the formula I according to claim 11, from its prodrug or a pharmaceutically acceptable salt the compound or prodrug for the manufacture of a medicament for the treatment of cardiac tissue ischemia in mammals or humans. Verwendung einer Verbindung der Formel I nach Anspruch 11, von deren Prodrug oder eines pharmazeutisch annehmbaren Salzes der Verbindung oder des Prodrug zur Herstellung eines Arzneimittels zur Behandlung von einer oder mehreren Komplikationen des Diabetes bei Säugetieren oder Menschen.Use of a compound of the formula I according to claim 11, from its prodrug or a pharmaceutically acceptable salt the compound or prodrug for the manufacture of a medicament for the treatment of one or more complications of diabetes in mammals or people. Verwendung nach Anspruch 13, wobei die Komplikationen ausgewählt sind aus diabetischer Neuropathie, diabetischer Nephropathie, diabetischer Kardiomyopathie, diabetischer Retinopathie, Katarakten, Fußgeschwüren, diabetischer Makroangiopathie und diabetischer Mikroangiopathie.Use according to claim 13, wherein the complications selected are from diabetic neuropathy, diabetic nephropathy, diabetic Cardiomyopathy, diabetic retinopathy, cataracts, foot ulcers, diabetic Macroangiopathy and diabetic microangiopathy. 3-Methoxy-6-(5-chlor-3-methyl-benzofuran-2-sulfenyl)-pyridazin, 3-Methoxy-6-(5-chlor-3-methyl-benzofuran-2-sulfonyl)-pyridazin oder 3-Methoxy-6-(5-chlor-3-methyl-benzofuran-2-sulfinyl)-pyridazin.3-Methoxy-6- (5-chloro-3-methyl-benzofuran-2-sulfenyl) -pyridazine, 3-Methoxy-6- (5-chloro-3-methyl-benzofuran-2-sulfonyl) -pyridazine or 3-methoxy-6- (5-chloro-3-methyl-benzofuran-2-sulfinyl) -pyridazine. Natriumsalz von 6-(5-Chlor-3-methyl-benzofuran-2-sulfonyl)-2H-pyridazin-3-on.Sodium salt of 6- (5-chloro-3-methyl-benzofuran-2-sulfonyl) -2H-pyridazin-3-one. Verbindung der Formel I nach Anspruch 11, deren Prodrug oder ein parmazeutisch annehmbares Salz der Verbindung oder des Prodrug zur Verwendung als Arzneimittel.A compound of the formula I according to claim 11, whose Prodrug or a parmaceutical compound of acceptable or salt the prodrug for use as a medicament.
DE60202452T 2001-03-30 2002-01-31 PYRIDAZINONAL DOSE REDUCTASE INHIBITORS Expired - Fee Related DE60202452C5 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28005101P 2001-03-30 2001-03-30
US280051P 2001-03-30
PCT/IB2002/000320 WO2002079198A1 (en) 2001-03-30 2002-01-31 Pyridazinone aldose reductase inhibitors

Publications (3)

Publication Number Publication Date
DE60202452D1 DE60202452D1 (en) 2005-02-03
DE60202452T2 DE60202452T2 (en) 2006-02-09
DE60202452C5 true DE60202452C5 (en) 2006-11-23

Family

ID=23071435

Family Applications (3)

Application Number Title Priority Date Filing Date
DE60216823T Expired - Fee Related DE60216823T2 (en) 2001-03-30 2002-01-31 Intermediates for the preparation of pyridazinone aldose reductase inhibitors.
DE60202452T Expired - Fee Related DE60202452C5 (en) 2001-03-30 2002-01-31 PYRIDAZINONAL DOSE REDUCTASE INHIBITORS
DE60217930T Expired - Fee Related DE60217930T2 (en) 2001-03-30 2002-01-31 Pyridazinone aldose reductase inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60216823T Expired - Fee Related DE60216823T2 (en) 2001-03-30 2002-01-31 Intermediates for the preparation of pyridazinone aldose reductase inhibitors.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60217930T Expired - Fee Related DE60217930T2 (en) 2001-03-30 2002-01-31 Pyridazinone aldose reductase inhibitors

Country Status (43)

Country Link
US (2) US6579879B2 (en)
EP (3) EP1491541B1 (en)
JP (1) JP2004528319A (en)
KR (1) KR100586138B1 (en)
CN (1) CN1215067C (en)
AP (1) AP2002002461A0 (en)
AR (1) AR035798A1 (en)
AT (3) ATE286049T1 (en)
AU (1) AU2002226634B2 (en)
BG (1) BG108179A (en)
BR (1) BR0208571A (en)
CA (1) CA2442476A1 (en)
CZ (1) CZ20032563A3 (en)
DE (3) DE60216823T2 (en)
DK (2) DK1373259T3 (en)
EA (1) EA006023B1 (en)
EC (1) ECSP034671A (en)
EE (1) EE200300470A (en)
ES (2) ES2274369T3 (en)
GE (1) GEP20053675B (en)
HR (1) HRP20030752A2 (en)
HU (1) HUP0303644A3 (en)
IL (1) IL156462A0 (en)
IS (3) IS2205B (en)
MA (1) MA27003A1 (en)
MX (1) MXPA03008850A (en)
MY (1) MY134304A (en)
NO (1) NO20034345L (en)
NZ (1) NZ528406A (en)
OA (1) OA12453A (en)
PA (1) PA8541801A1 (en)
PE (1) PE20030007A1 (en)
PL (1) PL365294A1 (en)
PT (2) PT1373259E (en)
SI (1) SI1373259T1 (en)
SK (1) SK11852003A3 (en)
TN (1) TNSN02037A1 (en)
TW (1) TWI245762B (en)
UA (1) UA73236C2 (en)
UY (1) UY27237A1 (en)
WO (1) WO2002079198A1 (en)
YU (1) YU71403A (en)
ZA (1) ZA200304671B (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0934061T1 (en) 1996-07-24 2003-10-31 Warner-Lambert Company Llc Isobutylgaba and its derivatives for the treatment of pain
DE60204611T2 (en) * 2001-02-28 2006-05-11 Pfizer Products Inc., Groton Sulfonyl-pyridazinone derivatives for use as aldose reductase inhibitors
KR100586138B1 (en) * 2001-03-30 2006-06-07 화이자 프로덕츠 인코포레이티드 Pyridazinone aldose reductase inhibitor
AU761191B2 (en) * 2001-05-24 2003-05-29 Pfizer Products Inc. Therapies for tissue damage resulting from ischemia
BR0306730A (en) * 2002-01-09 2004-12-21 Pfizer Prod Inc Process and intermediates for pyridazinone antidiabetic agents
US20040092522A1 (en) * 2002-08-15 2004-05-13 Field Mark John Synergistic combinations
US7419981B2 (en) * 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US6872833B2 (en) * 2003-04-14 2005-03-29 Hoffmann-La Roche Inc. Adenosine receptor ligands
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
AR049384A1 (en) 2004-05-24 2006-07-26 Glaxo Group Ltd PURINA DERIVATIVES
AU2005249794A1 (en) 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Pharmaceutical composition containing irbesartan
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
WO2006028565A2 (en) * 2004-06-30 2006-03-16 Whitehead Institute For Biomedical Research Novel methods for high-throughput genome-wide location analysis
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7645752B2 (en) * 2006-01-13 2010-01-12 Wyeth Llc Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors
CA2656003C (en) * 2006-06-27 2014-03-25 Tsuneo Yasuma Fused cyclic compounds
EP2094643B1 (en) 2006-12-01 2012-02-29 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
US8173645B2 (en) * 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
JP2010043063A (en) 2008-05-09 2010-02-25 Agency For Science Technology & Research Diagnosis and treatment of kawasaki disease
CA2783699C (en) 2009-12-08 2019-01-15 Case Western Reserve University Primary amine compounds for treating ocular disorders
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
AU2012308243B2 (en) * 2011-09-15 2017-09-14 Taipei Medical University Use of indolyl and indolinyl hydroxamates for treating heart failure of neuronal injury
US9339542B2 (en) * 2013-04-16 2016-05-17 John L Couvaras Hypertension reducing composition
CN105143203A (en) 2013-04-17 2015-12-09 辉瑞大药厂 N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
CN103739547B (en) * 2014-01-03 2015-09-02 沈阳药科大学 The synthetic method of 2-[6-methoxyl group-3-(2,3-dichlorophenyl) methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1 (4H)-quinolyl] acetic acid
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
AU2016248080A1 (en) * 2015-04-14 2017-11-02 Board Of Regents Of The University Of Texas System Compositions and methods of modulating short-chain dehydrogenase activity
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
NZ748506A (en) 2016-06-21 2025-07-25 Univ Columbia Aldose reductase inhibitors and methods of use thereof
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
WO2018058109A1 (en) * 2016-09-26 2018-03-29 Nusirt Sciences, Inc. Compositions and methods for treating metabolic disorders
JP7595413B2 (en) 2016-11-30 2024-12-06 ケース ウエスタン リザーブ ユニバーシティ Combination of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof - Patents.com
CA3052466A1 (en) 2017-02-06 2018-08-09 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
IL272246B1 (en) 2017-07-28 2025-09-01 Applied Therapeutics Inc Derivatives of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as aldose reductase inhibitors in treating galactosemia or preventing complications associated with galactosemia
US12336982B2 (en) 2018-11-21 2025-06-24 Rodeo Therapeutics Corporation Compositions and methods of modulating short-chain dehydrogenase activity
ES3007652T3 (en) 2019-01-18 2025-03-20 Astrazeneca Ab 6'-[[(1s,3s)-3-[[5-(difluoromethoxy)-2-pyrimidinyl]amino]cyclopentyl]amino][1(2h),3'-bipyridin]-2-one as pcsk9 inhibitor and methods of use thereof
AU2020268368A1 (en) 2019-05-07 2022-01-06 Ucl Business Ltd Treatment and detection of inherited neuropathies and associated disorders
SG11202113129UA (en) 2019-05-31 2021-12-30 Ikena Oncology Inc Tead inhibitors and uses thereof
MX2021014441A (en) 2019-05-31 2022-01-06 Ikena Oncology Inc Tead inhibitors and uses thereof.
WO2022120353A1 (en) * 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE47592B1 (en) 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4996204A (en) 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
FR2647676A1 (en) 1989-06-05 1990-12-07 Union Pharma Scient Appl New pyridazinone derivatives, processes for preparing them and medicaments containing them which are useful, in particular, as aldose reductase inhibitors
WO1992009594A1 (en) * 1990-11-30 1992-06-11 Tsumura & Co. Chromone derivative and aldose reductase inhibitor containing the same as active ingredient
AU658887B2 (en) 1991-03-28 1995-05-04 Pfizer Inc. Pyridazinone acetic acids as aldose reductase inhibitors
US5834466A (en) 1994-12-22 1998-11-10 The Regents Of The University Of California Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
JP2003525838A (en) * 1997-09-24 2003-09-02 オリオン コーポレーション Bisethers of 1-oxa, aza and thianaphthalen-2-one as phospholamban inhibitors
FR2822827B1 (en) * 2001-03-28 2003-05-16 Sanofi Synthelabo NOVEL N- (ARYLSULFONYL) BETA-AMINOACIDS DERIVATIVES COMPRISING A SUBSTITUTED AMINOMETHYL GROUP, THEIR PREPARATION METHOD AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
KR100586138B1 (en) * 2001-03-30 2006-06-07 화이자 프로덕츠 인코포레이티드 Pyridazinone aldose reductase inhibitor
CN1505514A (en) * 2001-04-30 2004-06-16 �Ʒ� Combination of aldose reductase inhibitors with cyclooxygenase-2 inhibitors
BR0306730A (en) * 2002-01-09 2004-12-21 Pfizer Prod Inc Process and intermediates for pyridazinone antidiabetic agents

Also Published As

Publication number Publication date
ES2231681T3 (en) 2005-05-16
EP1491540A1 (en) 2004-12-29
AU2002226634B2 (en) 2007-01-25
US6579879B2 (en) 2003-06-17
DE60216823D1 (en) 2007-01-25
ZA200304671B (en) 2004-06-25
ATE286049T1 (en) 2005-01-15
ECSP034671A (en) 2003-08-29
US20030162784A1 (en) 2003-08-28
SK11852003A3 (en) 2004-07-07
DK1491540T3 (en) 2007-03-26
NO20034345D0 (en) 2003-09-29
OA12453A (en) 2006-05-24
EA200300673A1 (en) 2003-12-25
KR100586138B1 (en) 2006-06-07
AR035798A1 (en) 2004-07-14
WO2002079198A1 (en) 2002-10-10
TNSN02037A1 (en) 2005-12-23
ATE352551T1 (en) 2007-02-15
CZ20032563A3 (en) 2004-05-12
US20020143017A1 (en) 2002-10-03
PT1491540E (en) 2007-01-31
PL365294A1 (en) 2004-12-27
MXPA03008850A (en) 2003-12-04
NZ528406A (en) 2004-03-26
CA2442476A1 (en) 2002-10-10
JP2004528319A (en) 2004-09-16
DE60202452D1 (en) 2005-02-03
PE20030007A1 (en) 2003-01-28
IS2205B (en) 2007-02-15
NO20034345L (en) 2003-09-29
HRP20030752A2 (en) 2005-06-30
YU71403A (en) 2006-05-25
DE60202452T2 (en) 2006-02-09
AP2002002461A0 (en) 2002-06-30
EA006023B1 (en) 2005-08-25
ATE348100T1 (en) 2007-01-15
EP1491541B1 (en) 2007-01-24
IS8250A (en) 2006-01-23
HUP0303644A2 (en) 2004-03-01
DE60217930D1 (en) 2007-03-15
BR0208571A (en) 2004-03-23
DE60217930T2 (en) 2007-10-18
UA73236C2 (en) 2005-06-15
MA27003A1 (en) 2004-12-20
CN1500087A (en) 2004-05-26
KR20030088484A (en) 2003-11-19
HUP0303644A3 (en) 2008-06-30
DK1373259T3 (en) 2005-03-29
PT1373259E (en) 2005-03-31
TWI245762B (en) 2005-12-21
EP1373259A1 (en) 2004-01-02
PA8541801A1 (en) 2002-10-28
IS6845A (en) 2003-06-16
HK1061678A1 (en) 2004-09-30
ES2274369T3 (en) 2007-05-16
CN1215067C (en) 2005-08-17
DE60216823T2 (en) 2007-10-04
SI1373259T1 (en) 2005-04-30
GEP20053675B (en) 2005-11-25
EE200300470A (en) 2004-02-16
US6849629B2 (en) 2005-02-01
UY27237A1 (en) 2002-12-31
EP1491541A1 (en) 2004-12-29
IL156462A0 (en) 2004-01-04
IS8251A (en) 2006-01-23
EP1491540B1 (en) 2006-12-13
MY134304A (en) 2007-12-31
BG108179A (en) 2004-09-30
EP1373259B1 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
DE60202452C5 (en) PYRIDAZINONAL DOSE REDUCTASE INHIBITORS
JP2004528319A5 (en)
EP2858983B1 (en) Tnf-alpha modulating benzimidazoles
DE60211348T2 (en) 2,4,5-TRISUBSTITUTED THIAZOLYL DERIVATIVES AND THEIR ANTIINFLAMMATORIC EFFECT
US6414149B1 (en) Sorbitol dehydrogenase inhibitors
AU2002363176B2 (en) Heteroaryl amines as glycogen synthase kinase 3Beta inhibitors (GSK3 inhibitors)
EP1442024B1 (en) AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3$g(b) INHIBITORS
US8993598B2 (en) Pyrrole compounds
DE60316709T2 (en) INDOLE-3-CARBONATEAUREAMIDES AS GLUCCOKINASE (GK) ACTIVATORS
KR101757959B1 (en) Nitrogen containing heteroaryl compounds
CA2685967A1 (en) Csf-1r inhibitors, compositions, and methods of use
JP2012246302A (en) Indole derivative as crac modulator
KR20100072075A (en) Csf-1r inhibitors for treatment of cancer and bone diseases
CA2642922A1 (en) Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
TWI422583B (en) Novel compound having 4-pyridylalkylthio group as substituent
AU2014234906A1 (en) Cycloalkyl nitrile pyrazolo pyridones as Janus kinase inhibitors
IL294247A (en) Heterocyclic compounds are useful as selective inhibitors of aurora a
ZA200307204B (en) Combinations of aldose reductase inhibitors and cyclooxygenase-2-inhibitors.
JPS63301880A (en) 5-fluorouracil derivative
WO2024148210A1 (en) Cyclin-dependent kinase 12 modulators and therapeutic uses thereof
HK1251815A1 (en) 1-(het)arylsulfonyl-(pyrrolidine or piperidine)-2-carboxamide derivatives and their use as trpa1 antagonists
HK1077507B (en) 2,4,5-trisubstituted thiazolyl derivatives ant their antiinflammatory activity
HK1062888A1 (en) Vinyl phenyl derivatives as glk activators

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8315 Request for restriction filed
8318 Patent restricted
8393 Patent changed during the limitation procedure (changed patent specification reprinted)
8339 Ceased/non-payment of the annual fee